401 related articles for article (PubMed ID: 27031294)
1. Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus.
So WY; Leung PS
Med Res Rev; 2016 Jul; 36(4):672-704. PubMed ID: 27031294
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice.
Kim HW; Lee JE; Cha JJ; Hyun YY; Kim JE; Lee MH; Song HK; Nam DH; Han JY; Han SY; Han KH; Kang YS; Cha DR
Endocrinology; 2013 Sep; 154(9):3366-76. PubMed ID: 23825123
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus.
Dostálová I; Haluzíková D; Haluzík M
Physiol Res; 2009; 58(1):1-7. PubMed ID: 19331512
[TBL] [Abstract][Full Text] [Related]
4. Relationship between FGF21 and drug or nondrug therapy of type 2 diabetes mellitus.
Guo C; Zhao L; Li Y; Deng X; Yuan G
J Cell Physiol; 2021 Jan; 236(1):55-67. PubMed ID: 32583417
[TBL] [Abstract][Full Text] [Related]
5. Metabolic actions of fibroblast growth factor 21.
Cuevas-Ramos D; Aguilar-Salinas CA; Gómez-Pérez FJ
Curr Opin Pediatr; 2012 Aug; 24(4):523-9. PubMed ID: 22732636
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases.
Kharitonenkov A; Shanafelt AB
BioDrugs; 2008; 22(1):37-44. PubMed ID: 18215089
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 21: a regulator of metabolic disease and health span.
Xie T; Leung PS
Am J Physiol Endocrinol Metab; 2017 Sep; 313(3):E292-E302. PubMed ID: 28559437
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor-21, energy balance and obesity.
Giralt M; Gavaldà-Navarro A; Villarroya F
Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():66-73. PubMed ID: 26415590
[TBL] [Abstract][Full Text] [Related]
9. The Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes.
Izaguirre M; Gil MJ; Monreal I; Montecucco F; Frühbeck G; Catalán V
Curr Diab Rep; 2017 Jun; 17(6):43. PubMed ID: 28451950
[TBL] [Abstract][Full Text] [Related]
10. FGF21: a novel prospect for the treatment of metabolic diseases.
Kharitonenkov A; Shanafelt AB
Curr Opin Investig Drugs; 2009 Apr; 10(4):359-64. PubMed ID: 19337957
[TBL] [Abstract][Full Text] [Related]
11. FGF21-based pharmacotherapy--potential utility for metabolic disorders.
Gimeno RE; Moller DE
Trends Endocrinol Metab; 2014 Jun; 25(6):303-11. PubMed ID: 24709036
[TBL] [Abstract][Full Text] [Related]
12. Impact of FGF21 on glycemic control.
Strowski MZ
Horm Mol Biol Clin Investig; 2017 Jun; 30(2):. PubMed ID: 28593912
[TBL] [Abstract][Full Text] [Related]
13. Metformin-induced inhibition of the mitochondrial respiratory chain increases FGF21 expression via ATF4 activation.
Kim KH; Jeong YT; Kim SH; Jung HS; Park KS; Lee HY; Lee MS
Biochem Biophys Res Commun; 2013 Oct; 440(1):76-81. PubMed ID: 24041694
[TBL] [Abstract][Full Text] [Related]
14. [THE ROLE OF FIBROBLAST GROWTH FACTOR 21 (FGF21) IN THE REGULATION AND CORRECTION OF CARBOHYDRATE AND LIPID METABOLISM].
Marakova EN; Bazhan NM
Ross Fiziol Zh Im I M Sechenova; 2016 Dec; 102(12):1406-16. PubMed ID: 30198244
[TBL] [Abstract][Full Text] [Related]
15. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21.
Iglesias P; Selgas R; Romero S; Díez JJ
Eur J Endocrinol; 2012 Sep; 167(3):301-9. PubMed ID: 22740503
[TBL] [Abstract][Full Text] [Related]
16. FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases.
Sonoda J; Chen MZ; Baruch A
Horm Mol Biol Clin Investig; 2017 May; 30(2):. PubMed ID: 28525362
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factors: new insights, new targets in the management of diabetes.
Kyrou I; Weickert MO; Gharanei S; Randeva HS; Tan BK
Minerva Endocrinol; 2017 Sep; 42(3):248-270. PubMed ID: 27412358
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor 21: from pharmacology to physiology.
Kliewer SA; Mangelsdorf DJ
Am J Clin Nutr; 2010 Jan; 91(1):254S-257S. PubMed ID: 19906798
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast Growth Factor-Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications.
Jin L; Yang R; Geng L; Xu A
Annu Rev Pharmacol Toxicol; 2023 Jan; 63():359-382. PubMed ID: 36100222
[TBL] [Abstract][Full Text] [Related]
20. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1.
Wu AL; Kolumam G; Stawicki S; Chen Y; Li J; Zavala-Solorio J; Phamluong K; Feng B; Li L; Marsters S; Kates L; van Bruggen N; Leabman M; Wong A; West D; Stern H; Luis E; Kim HS; Yansura D; Peterson AS; Filvaroff E; Wu Y; Sonoda J
Sci Transl Med; 2011 Dec; 3(113):113ra126. PubMed ID: 22174314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
